{
    "clinical_study": {
        "@rank": "19957", 
        "brief_summary": {
            "textblock": "A Cumulative Patch Test with a Challenge Phase is a test devised to ascertain if a chemical\n      agent or agents have the potential to cause contact irritation or contact allergy in the\n      skin.  Allergy is only elicited in immunologically competent individuals who have become\n      sensitized through exposure to the chemical agent at a sufficient concentration and for a\n      sufficient duration of time."
        }, 
        "brief_title": "Cumulative Irritation Patch Test", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Allergy", 
            "Irritation", 
            "Sensitization"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must not have any visible skin disease that might be confused with a skin\n             reaction to the test trial;\n\n          -  Subjects must not be participating in another clinical trial at this facility or any\n             other facility;\n\n          -  Subjects must be willing to avoid using topical or systemic steroids or\n             antihistamines for at least 7 days prior to trial initiation and during the duration\n             of the trial;\n\n          -  Subjects must understand and execute and Informed Consent Form;\n\n          -  Subjects must be capable of understanding and following directions;\n\n          -  Subjects must be considered reliable;\n\n          -  Subjects must be aged 16 to 79 years, inclusive;\n\n          -  Subjects aged less than 18 years must have a parent or legal guardian execute the\n             Informed Consent Form.\n\n        Exclusion Criteria:\n\n          -  Subjects in ill health or taking medications, other than birth control, which could\n             influence the purpose, integrity or outcome of the trial;\n\n          -  Female subjects who report orally they are pregnant, planning to become pregnant or\n             nursing during the course of the trial;\n\n          -  Subjects who have a history of adverse reactions to adhesive tape, cosmetics,\n             Over-The-Counter drugs or other personal care products;\n\n          -  Subjects judged by the PI to be inappropriate for the trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "79 Years", 
            "minimum_age": "16 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Approximately 240 subjects will be enrolled in the trial so that at least 200 subjects\n        will complete the trial.  Subjects who meet all of the inclusion criteria  and none of the\n        exclusion criteria  will be eligible to enroll into the trial."
            }
        }, 
        "enrollment": {
            "#text": "224", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01842711", 
            "org_study_id": "CTTA01-010"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 29, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fairfield", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07004"
                }, 
                "name": "Consumer Product Testing Company, Inc."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Exclusive Cumulative Irritation Patch Test (21 Day) With Challenge Patch Application", 
        "overall_official": {
            "affiliation": "Consumer Product Testing Company", 
            "last_name": "Michael Caswell, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "This will be measured by the evaluation of the test sites (skin)by a trained assessor with a predetermined scale for skin irritation.", 
            "measure": "Primary or Cumulative Irritation Potential of the skin", 
            "safety_issue": "Yes", 
            "time_frame": "21 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01842711"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "After the repeated application period of the test material, a rest period will be employed.  The test material will be applied to a na\u00efve site and then will be evaluated by a trained assessor with a predetermined scale for skin irritation.", 
            "measure": "Allergic Contact Sensitization Potential", 
            "safety_issue": "Yes", 
            "time_frame": "21 days"
        }, 
        "source": "Chattem, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chattem, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "April 2013"
    }
}